RNA

RNA is currently trading as a complex merger-arbitrage vehicle rather than a standard directional breakout. The stock is pinned slightly above the $72.00/share cash acquisition offer from Novartis, with the $0.93 premium reflecting the implied value of the 'Atrium Therapeutics' spin-off (cardiology assets) scheduled for distribution. The 'Quiet Storm' signal and effectively zero realized volatility (2.3% annualized) confirm price action is pegged to the deal terms, while the volume spike represents event-driven desks positioning ahead of the just-announced Feb 12 record date.